濟川藥業(600566.SH):放棄蒲地藍日化的增資優先認購權
格隆匯8月1日丨濟川藥業(600566.SH)公佈,公司通過全資子公司濟川藥業集團有限公司(“濟川有限”)原持有江蘇蒲地藍日化有限公司(“蒲地藍日化”)100%股權。公司控股股東江蘇濟川控股集團有限公司(“濟川控股”)的控股子公司西藏嘉澤創業投資有限公司(“西藏嘉澤”)擬以現金5000萬元認繳蒲地藍日化新增註冊資本192.3萬元,濟川有限同意就此次增資放棄優先認購權。
增資完成後,蒲地藍日化註冊資本由500萬元增加至692.30萬元,濟川有限持有蒲地藍日化72.22%的股權,西藏嘉澤持有蒲地藍日化27.78%的股權,蒲地藍日化由公司全資子公司變為控股子公司。
濟川有限、西藏嘉澤及蒲地藍日化已於2021年7月30日簽署了《 濟川藥業集團有限公司與西藏嘉澤創業投資有限公司關於江蘇蒲地藍日化有限公司之增資協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.